Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

rifosine plus bortezomib, there were 2 PR's and 1 MR. Two additional MR's were observed on this combination after dexamethasone was added; both of these patients were previously refractory to the combination of bortezomib + dexamethasone without perifosine. Eleven patients remain on study and the phase II portion of the study is now open and enrolling.

A second poster presented by Dr. Richardson, entitled " Perifosine (KRX- 0401) + Low Dose Dexamethasone is Active in Patients with Relapsed and Refractory Multiple Myeloma (MM): Perifosine MM Investigator Group Phase II Multicenter Study Update" demonstrated that 78% of patients treated with perifosine plus low dose dexamethasone had at least stable disease (SD), including 26% that had a PR or MR. Patients continue on study now ranging from 6 months up through 1 year.

Dr. Andrzej Jakubowiak, Director of the myeloma program at the University of Michigan Cancer Center, presented a poster entitled "A Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results. Multiple Myeloma Research Consortium (MMRC) Trial", demonstrating early encouraging results, with 50% of patients achieving a partial response or better.

Commenting on the data, Dr. Richardson stated, "Perifosine's potential in combination with bortezomib, dexamethasone and other novel therapies to overcome drug-resistant multiple myeloma is promising. Our team of investigators, including top centers across the country and now incorporating the considerable resources of the MMRC for one of the trials, is committed to completing enrollment in our studies and evaluating future clinical strategies to improve patient outcome."

Perifosine in the treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia:

A poster entitled "A Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Wald
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation ... generic market entry results in $5.4 billion in lost ... analysis by economic consulting firm Matrix Global ... Required by the Food and Drug ... programs are intended to improve drug safety by ensuring ...
(Date:7/23/2014)...  When it comes to welcoming our new robot overlords, ... out the red carpet. Healthcare is one of ... robots into our human sphere. With healthcare concerns top of ... to apply new technologies to help with old problems. That,s ... is expected to increase from $1.7 billion now to $3.7 ...
(Date:7/23/2014)... , July 23, 2014  Nearly 8,000 attendees will ... Cardinal Health,s annual Retail Business Conference (RBC), taking place ... Center. This year,s event encourages pharmacists to "Lead Change" ... communities and for their future. ... to network with their peers and learn new ways ...
Breaking Medicine Technology:New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6
... Telik, Inc. (Nasdaq: TELK ) today ... Research (AACR) Annual Meeting in Orlando, Florida on a ... clinically advanced product in development at Telik.  Ezatiostat is ... validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully ...
... YONKERS, N.Y., April 5, 2011 New drugstore Ratings published ... available online at www.ConsumerReportsHealth.org reveal that the overwhelming ... at neighborhood independent drugstores. While customers said they were generally ... and lagging service at some big box stores. ...
Cached Medicine Technology:Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting 2Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting 3Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting 4Consumer Reports' Drugstore Ratings: 94% of Shoppers "Highly Satisfied" With Independents; Some Irked By Long Waits at Big Box Stores 2Consumer Reports' Drugstore Ratings: 94% of Shoppers "Highly Satisfied" With Independents; Some Irked By Long Waits at Big Box Stores 3Consumer Reports' Drugstore Ratings: 94% of Shoppers "Highly Satisfied" With Independents; Some Irked By Long Waits at Big Box Stores 4
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
(Date:7/23/2014)... Global Cardio Care, Inc., a management company ... is celebrating the 100th birthday of Albert Weber, ... center. , Weber has been plagued with angina ... therapy since 1999, he no longer suffers from either ... Cardio Care, introduced the Sara Soulati Health For ...
(Date:7/23/2014)... The voice on the recording was low and calm as ... was infected with the human immunodeficiency virus (HIV) that causes AIDS: ... you know I was on the floor flat on my face ... when the recording ended less than 10 minutes later. “Don’t feel ... because it is just God setting you up for something greater,” ...
(Date:7/23/2014)... For patients infected with both HIV and hepatitis C, ... a small study suggests. Researchers said doctors could ... with the two diseases. "The findings suggest ... role in the management of individuals with [hepatitis C] ... a professor of medicine at the University of Cincinnati ...
(Date:7/23/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown clinics ... Orthopaedic Certified Specialist (OCS) or Sports ... DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason Brown, ... Leech, PT, DPT, OCS, and Mary Grimberg, PT, DPT, ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... urge more awareness that long-term use has consequences , ... and other cardiovascular problems appear to be more common ... androgen deprivation therapy, which reduces or eliminates the male ... study has found. , The finding indicates that androgen ...
... Tamiflu Oral Suspension ... ... (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping additional quantities of ... begin arriving in pharmacies nationwide and will continue to roll out to wholesale and retail ...
... The following is an op-ed written by Fredette West, Director, African ... how can the nation can pay for health reform; and in ... all the talk about finding "off-sets" -- media, legislators, and analysts, ... studies from Johns Hopkins University and the University of Maryland. A ...
... Initiates Training Program Partnering with Healthcare Employers , WEST ... a $134,790 grant by the State of Florida to fund ... for skilled health care workers in Palm Beach County. ... Healthcare Workforce Initiative. The funding enables Workforce Alliance to ...
... can,t teach an old dog new tricks," it,s often said. ... to be passed down from generation to generation. , "While some ... them and act on them," says Mark Nunez, DVM, president of ... veterinarian to find out if a commonly held belief is really ...
... ― Two medications approved as treatment for drug-resistant chronic ... responses as a first treatment than the existing front-line ... Anderson Cancer Center reported at the 51st Annual Meeting ... for CML remains imatinib, a Novartis drug known as ...
Cached Medicine News:Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Health Reform is About You and Me, Not One or the Other 2Health News:Health Reform is About You and Me, Not One or the Other 3Health News:Workforce Alliance Earns Grant to Train Health Care Workers 2Health News:Workforce Alliance Earns Grant to Train Health Care Workers 3Health News:Some Myths About Dogs and Cats Are Not Only False - They're Dangerous! 2Health News:Second-line CML drugs evoke faster response than front-line therapy 2
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: